

Meningococcal disease

Reported cases of invasive meningococcal infections, including sepsis and meningitis, have declined from the hyperendemic levels seen in 1993–1997 attributable to a clonal strain of serogroup B *Neisseria meningitidis*. Respiratory secretions and droplets continue to be shared among Oregonians and predispose us to secondary cases.

In 2016, there were 24 reported cases and one death from meningococcal disease in Oregon. From the early 1990s through 2011, serogroup B predominated in Oregon, but in 2011 and again in 2013–2014, other serogroups have been more prominent. In 2015 serogroup B accounted for 52% (14) of the serogrouped cases, whereas 26% (7) of cases were serogroup C. In 2016, 42% of cases were serogroup B; serogroup C accounted for 46% of the cases. In 2016, there was a meningococcal serogroup B outbreak in a large public university, with three cases among university students. Two mass vaccination clinics were held at the university with the goal of vaccinating all undergraduate students.


The burden of meningococcal disease was highest in those ≤ 5 years of age (2.9/100,000). Meningococcal disease is treated with intravenous antibiotics.

American Committee on Immunization Practices (ACIP) recommends routine vaccination with quadrivalent (contains antigens from serogroups A, C, Y and W-135) meningococcal conjugate vaccine for all persons 11–21 years of age. Meningococcal vaccine is also recommended for persons 2 months to 55 years of age who are at increased risk for the disease due to complement deficiency, travel to or residence in a country where meningococcal disease is hyperendemic or epidemic, or inclusion in a defined risk group during a community or institutional outbreak.


In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal vaccine (MenB-FHbp, Trumenba®). FDA approved this vaccine for use in people 10–25 years of age as a three-dose series. On Jan. 23, 2015, FDA licensed a second serogroup B meningococcal vaccine (MenB-4C, Bexsero®). FDA approved this vaccine for use in people 10–25 years of age as a two-dose series.

MenB vaccination is now recommended for those ≥ 10 years of age with complement deficiencies, anatomic or functional asplenia, microbiologists who have contact with *N. meningitidis*, and others at increased risk during a serogroup B outbreak. MenB vaccine may also be administered to adolescents and young adults 16–23 years of age to provide short-term protection against most strains of serogroup B meningococcal disease.


Meningococcal disease by year: Oregon, 1988–2016




Meningococcal disease by onset month: Oregon, 2016



Incidence of meningococcal disease by age and sex: Oregon, 2007–2016




Incidence of meningococcal disease: Oregon vs. nationwide, 2002–2016




Oregon	1.3	1.7	1.7	1.6	1.1	0.9	1.0	1.1	0.8	0.8	0.7	0.3	0.5	0.7	0.6
U.S.	0.6	0.6	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.1	0.1	0.1

Meningococcal disease by serogroup: Oregon, 2007–2016



B	16	21	17	14	6	11	3	4	14	10
C	6	7	2	6	9	5	5	8	7	11
W135	2	4	2	3	3	2	1	1	2	1
Y	6	5	14	8	10	6	1	2	4	1

Incidence of meningococcal disease by county of residence: Oregon, 2007–2016



Prevention

- Vaccinate to prevent illness from serogroups A, C, Y, W-135 per ACIP guidelines.
- Vaccinate to prevent illness from serogroup B per ACIP guidelines.
- Identify and recommend prophylaxis of close contacts of confirmed and presumptive cases.
- Avoid smoking and exposing children to tobacco smoke, which have been associated with an increased risk of invasive meningococcal disease.